Table of Contents
ISRN Pain
Volume 2013, Article ID 452957, 4 pages
http://dx.doi.org/10.1155/2013/452957
Clinical Study

Intravenous Methadone for Severe Cancer Pain: A Presentation of 10 Cases

Supportive and Palliative Care Unit, Institut Jules Bordet, Waterloo Boulevard 121, 1000 Brussels, Belgium

Received 18 September 2012; Accepted 18 October 2012

Academic Editors: S. Coaccioli and C. Laurido

Copyright © 2013 D. Lossignol et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. W. Hanks, F. D. Conno, N. Cherny et al., “Morphine and alternative opioids in cancer pain: the EAPC recommendations,” British Journal of Cancer, vol. 84, no. 5, pp. 587–593, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Caraceni, G. Hanks, S. Kaasa et al., “Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendation from the EAPC,” The Lancet Oncology, vol. 13, no. 2, pp. e58–e68, 2012. View at Google Scholar
  3. L. Shaiova, “The role of methadone in the treatment of moderate to severe cancer pain,” Supportive Cancer Therapy, vol. 2, pp. 176–180, 2005. View at Google Scholar
  4. F. De Conno, L. Groff, C. Brunelli, E. Zecca, V. Ventafridda, and C. Ripamonti, “Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients,” Journal of Clinical Oncology, vol. 14, no. 10, pp. 2836–2842, 1996. View at Google Scholar · View at Scopus
  5. C. Ripamonti, L. Groff, C. Brunelli, D. Polastri, A. Stavrakis, and F. De Conno, “Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?” Journal of Clinical Oncology, vol. 16, no. 10, pp. 3216–3221, 1998. View at Google Scholar · View at Scopus
  6. P. W. Walker, S. Palla, B. L. Pei et al., “Switching from methadone to a different opioid: what is the equianalgesic dose ratio?” Journal of Palliative Medicine, vol. 11, no. 8, pp. 1103–1108, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. C. A. Kornick, M. J. Kilborn, J. Santiago-Palma et al., “QTc interval prolongation associated with intravenous methadone,” Pain, vol. 105, no. 3, pp. 499–506, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Sekine, E. A. M. T. Obbens, N. Coyle, and C. E. Inturrisi, “The successful use of parenteral methadone in a patient with a prolonged QTc Interval,” Journal of Pain and Symptom Management, vol. 34, no. 5, pp. 566–569, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Ripamonti, E. Bandieri, and F. Roila, “Management of cancer pain: ESMO clinical practice guidelines,” Annals of Oncology, vol. 22, supplement 6, pp. 69–77, 2011. View at Google Scholar
  10. D. R. Fitzgibbon and L. B. Ready, “Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high-dose morphine,” Pain, vol. 73, no. 2, pp. 259–261, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. D. A. Lossignol, M. Obiols-Portis, and J. J. Body, “Successful use of ketamine for intractable cancer pain,” Supportive Care in Cancer, vol. 13, no. 3, pp. 188–193, 2005. View at Publisher · View at Google Scholar · View at Scopus